Neomycin Oral Product — Competitive Intelligence Brief

Neomycin Oral Product (Neomycin Oral Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside antibiotic. Area: Infectious Disease.

marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Neomycin Oral Product (Neomycin Oral Product) — South Australian Health and Medical Research Institute. Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Neomycin Oral Product TARGET	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
topical tetracycline	topical tetracycline	Johns Hopkins University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
DoxyPEP	DoxyPEP	Chinese University of Hong Kong	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline Hyclate Enteric-Coated Capsules	Doxycycline Hyclate Enteric-Coated Capsules	The Third Xiangya Hospital of Central South University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tobramycin once a day	Tobramycin once a day	Oslo University Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Tobramycin + Dexamethasone	Tobramycin + Dexamethasone	Umm Al-Qura University	marketed	Antibiotic + corticosteroid combination	Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside antibiotic class)

1. U.S. Army Medical Research and Development Command · 2 drugs in this class
2. Hospital General Universitario Elche · 2 drugs in this class
3. Murdoch Childrens Research Institute · 2 drugs in this class
4. Public Health Service of Amsterdam · 1 drug in this class
5. Seattle Children's Hospital · 1 drug in this class
6. Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
7. Shanghai Zhongshan Hospital · 1 drug in this class
8. South Australian Health and Medical Research Institute · 1 drug in this class
9. The University of Queensland · 1 drug in this class
10. University of Leipzig · 1 drug in this class